December 2010 Safety Labeling Changes: 58 Medical Product Labels with changes to Boxed Warnings, Contraindications, Precautions, Adverse Reactions

The MedWatch December 2010 Safety Labeling Changes posting includes 58 products with safety labeling changes to the following sections: BOXED WARNINGS, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, PATIENT PACKAGE INSERT, and MEDICATION GUIDE.

The "Summary Page" provides a listing of drug names and safety labeling sections revised:

http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm235838.htm

Clicking on a drug product name in the Summary View will take you to the "detailed view" page, which identifies safety labeling sections and subsections revised, along with a brief summary of new or modified safety information.

The following drugs had modifications to the BOXED WARNINGS, CONTRAINDICATIONS and WARNINGS sections:

Ablavar (gadofosveset trisodium)
Aceon (perindopril erbumine)
Baraclude (entecavir)
Copegus (ribavirin)
Eovist (Gadoxetate disodium) injection
Innopran XL (propranolol hydrochloride)
Magnevist (gadopentetate dimeglumine)
MultiHance (gadobenate dimeglumine)
Omniscan (gadodiamide)
Optimark (gadoversetamide)
Prilosec OTC (omeprazole magnesium)
Pristiq (desvenlafaxine)
Prohance (gadoteridol)
Relenza (zanamivir)
Remicade (inflximab)
Terconazole Vaginal Cream
Zegerid OTC capsules
Zerit (stavudine)
Fresh from the show floor: pharma packaging innovations for 2026
Serialization mandates. Containment demands. Sterile barrier requirements. Our editors found the pharma packaging innovations addressing your biggest challenges at PACK EXPO Las Vegas. Get your free curated report now.
GET YOUR COPY
Fresh from the show floor: pharma packaging innovations for 2026